1. Introduction {#sec1-cancers-11-00415}
===============

Lung cancer (LC) is the leading cause of cancer mortality in Eastern Asia, with 950,015 cases and 815,635 deaths estimated in 2018 \[[@B1-cancers-11-00415]\]. Although advances in therapy have led to improvements in survival of LC patients \[[@B2-cancers-11-00415]\], the 5-year survival rate remains very low, mainly due to late diagnosis of disease \[[@B3-cancers-11-00415]\]. Traditional screening methods such as chest radiography and sputum cytology have limited clinical applications as they display low sensitivity and specificity in detection of LC \[[@B4-cancers-11-00415]\]. In recent years, Low-dose CT has been recommended for LC screening in high-risk smokers. However, potential hazards of CT screening, including radiation exposure, high false-positive rates, overdiagnosis and high cost, raise concerns \[[@B5-cancers-11-00415],[@B6-cancers-11-00415]\]. Therefore, in order to reduce LC mortality, effective methods for early diagnosis of LC remain desirable.

MicroRNAs (miRNAs) are a class of single stranded RNAs composed of 18--22 nucleotides, which are involved in the regulation of gene transcription but have no protein coding function, and are widely present in eukaryotic cells \[[@B7-cancers-11-00415]\]. At present, several studies have identified abnormally expressed miRNA patterns in blood specimens of LC patients, such as plasma, serum and exosome, suggesting that circulating miRNA may be useful for LC diagnosis \[[@B8-cancers-11-00415],[@B9-cancers-11-00415],[@B10-cancers-11-00415]\].

Because of the genetic diversity of miRNA expression profiles of populations \[[@B11-cancers-11-00415]\], we previously summarized the diagnostic performance of circulating miRNAs restricted to Western populations \[[@B12-cancers-11-00415]\]. Herein, we systematically reviewed their diagnostic performance in East Asian populations, paying particular attention to the potential differences between the East Asian and Western populations.

2. Methods {#sec2-cancers-11-00415}
==========

This systematic review was conducted in accordance with PRISMA recommendations \[[@B13-cancers-11-00415]\].

2.1. Literature Search {#sec2dot1-cancers-11-00415}
----------------------

A systematic literature search was carried out to identify all studies that evaluated circulating miRNAs related to LC. We searched the PubMed and ISI Web of Science databases for relevant articles from inception to 17 September, 2018, using the following keyword combinations: ((lung OR pulmonary) AND (cancer OR carcinoma OR neoplasm OR tumor OR adenocarcinoma OR squamous carcinoma OR malignancy) AND (microRNA\* OR miRNA\* OR miR\* OR let-7\*) AND (detection OR diagnosis OR biomarker OR marker) AND (blood OR serum OR plasma)). Duplicate articles were removed.

2.2. Eligibility Criteria {#sec2dot2-cancers-11-00415}
-------------------------

Based on the reading of titles and abstracts, we excluded: (1) non-English articles; (2) non-original articles; (3) not lung cancer studies; (4) non-human studies; (5) studies not based on plasma/serum samples; (6) studies not relevant to the topic; (7) no full text articles ([Figure 1](#cancers-11-00415-f001){ref-type="fig"}). The second round of screening was performed by reading full text of articles. In this step, the following studies were excluded: (1) studies using disease controls; (2) studies not reporting key data on diagnostic performance of miRNA markers (such as simple size, sensitivity, specificity, or area under the curve (AUC); (3) Non-East Asian studies.

2.3. Data Extraction and Statistical Analysis {#sec2dot3-cancers-11-00415}
---------------------------------------------

Two reviewers (H.Y. and Z.G.) independently read and extracted data from the studies that complied with the inclusion and exclusion criteria described above. From each study, we extracted available data on first author, publication year, country, study design, basic population characteristics (including size, age and sex distribution, and histological type and tumor stage for cases), type of bio-specimen, miRNA measurement method, targeted miRNA markers and diagnostic performance related indicators (including sensitivity, specificity, AUC and *p*-value). Individual miRNAs with *p*-value \> 0.05 were dropped. Mean or median age and male proportion of included studies were calculated by statistical software R (version 3.3.3, R Foundation, Vienna, Austria) if this information was not reported but raw data were available. Different name versions of the same miRNAs were incorporated according to the accession number of miRBase provided (<http://www.mirbase.org/>). Any disagreements were discussed and resolved among the authors.

2.4. Quality Assessment {#sec2dot4-cancers-11-00415}
-----------------------

We employed QUADAS-2, an updated and widely recommended tool for quality assessment of diagnostic accuracy studies, to assess the quality of each included study. Four key domains of QUADAS-2 were assessed, i.e., patient selection, index test, reference standard and flow and timing. Each domain is evaluated for risk of bias and the first three domains are evaluated for applicability. QUADAS-2 assessment was conducted utilizing the software Review Manager (version 5.3.5, Cochrane Collaboration, Copenhagen, Denmark).

3. Results {#sec3-cancers-11-00415}
==========

3.1. Literature Search Result {#sec3dot1-cancers-11-00415}
-----------------------------

Our literature search initially yielded 1543 articles using the search terms mentioned above, 551 from PubMed and 992 from Web of Science ([Figure 1](#cancers-11-00415-f001){ref-type="fig"}). After removal of 340 duplicate articles, titles and abstracts of 1203 articles were carefully reviewed. A total of 1097 articles were excluded according to the above described exclusion criteria. The remaining 106 articles were selected for full text reading, of which 60 articles were removed: 24 using disease controls, 16 not reporting sensitivity, specificity or AUC values, and 20 reporting studies in non-East Asian countries. In the end, 46 studies that evaluated diagnostic performance of circulating miRNAs for LC in East Asian populations and published between 2011 and 2018 ([Table 1](#cancers-11-00415-t001){ref-type="table"} and [Table 2](#cancers-11-00415-t002){ref-type="table"}) were eligible for this systematic review \[[@B8-cancers-11-00415],[@B9-cancers-11-00415],[@B10-cancers-11-00415],[@B14-cancers-11-00415],[@B15-cancers-11-00415],[@B16-cancers-11-00415],[@B17-cancers-11-00415],[@B18-cancers-11-00415],[@B19-cancers-11-00415],[@B20-cancers-11-00415],[@B21-cancers-11-00415],[@B22-cancers-11-00415],[@B23-cancers-11-00415],[@B24-cancers-11-00415],[@B25-cancers-11-00415],[@B26-cancers-11-00415],[@B27-cancers-11-00415],[@B28-cancers-11-00415],[@B29-cancers-11-00415],[@B30-cancers-11-00415],[@B31-cancers-11-00415],[@B32-cancers-11-00415],[@B33-cancers-11-00415],[@B34-cancers-11-00415],[@B35-cancers-11-00415],[@B36-cancers-11-00415],[@B37-cancers-11-00415],[@B38-cancers-11-00415],[@B39-cancers-11-00415],[@B40-cancers-11-00415],[@B41-cancers-11-00415],[@B42-cancers-11-00415],[@B43-cancers-11-00415],[@B44-cancers-11-00415],[@B45-cancers-11-00415],[@B46-cancers-11-00415],[@B47-cancers-11-00415],[@B48-cancers-11-00415],[@B49-cancers-11-00415],[@B50-cancers-11-00415],[@B51-cancers-11-00415],[@B52-cancers-11-00415],[@B53-cancers-11-00415],[@B54-cancers-11-00415],[@B55-cancers-11-00415],[@B56-cancers-11-00415]\]. Of the included 46 studies, 45 were from China and one was from Japan \[[@B29-cancers-11-00415]\].

3.2. Study Quality and Characteristics {#sec3dot2-cancers-11-00415}
--------------------------------------

QUADAS-2 assessment was completed by two reviewers (H.Y. and Z.G.) independently. Any inconsistencies were discussed and resolved between the investigators. High applicability concerns were found in the patient selection domain in 10 (22%) of the included studies. Unclear risk of bias were found in the patient selection domain and the index test domain in 24 (52%) and 6 (13%) of the included studies, respectively. No risk of bias or applicability concern was found in the reference standard domain, and the flow and timing domain. Details of QUADAS-2 results of the 46 studies are displayed in [Figures S1 and S2](#app1-cancers-11-00415){ref-type="app"}.

All 46 studies were case-control studies in which blood samples were collected after disease diagnosis. Of the 46 studies, 43 evaluated individual miRNAs, eight of which conducted independent validation ([Table 1](#cancers-11-00415-t001){ref-type="table"}). Sixteen studies assessed miRNA panels, 13 of which carried out independent validation ([Table 2](#cancers-11-00415-t002){ref-type="table"}). Detailed information on each study, including the number of cases and controls, mean or median age, male proportion, specimen type, histological subtype, tumor stage, and diagnostic indicators, are summarized in [Table 1](#cancers-11-00415-t001){ref-type="table"} and [Table 2](#cancers-11-00415-t002){ref-type="table"}. [Table 1](#cancers-11-00415-t001){ref-type="table"} additionally shows the p-value for testing the difference of each individual miRNA between cases and controls or the statistical significance of AUC values (indicated in the footnotes of [Table 1](#cancers-11-00415-t001){ref-type="table"}).

The median numbers (range) of LC cases and controls were 94 (11--514) and 60 (11--360), respectively. Fifteen studies examined miRNAs in plasma \[[@B10-cancers-11-00415],[@B16-cancers-11-00415],[@B19-cancers-11-00415],[@B21-cancers-11-00415],[@B27-cancers-11-00415],[@B31-cancers-11-00415],[@B37-cancers-11-00415],[@B41-cancers-11-00415],[@B42-cancers-11-00415],[@B43-cancers-11-00415],[@B48-cancers-11-00415],[@B50-cancers-11-00415],[@B55-cancers-11-00415],[@B56-cancers-11-00415],[@B57-cancers-11-00415]\], 30 in serum \[[@B9-cancers-11-00415],[@B14-cancers-11-00415],[@B15-cancers-11-00415],[@B17-cancers-11-00415],[@B18-cancers-11-00415],[@B20-cancers-11-00415],[@B23-cancers-11-00415],[@B24-cancers-11-00415],[@B25-cancers-11-00415],[@B26-cancers-11-00415],[@B28-cancers-11-00415],[@B29-cancers-11-00415],[@B30-cancers-11-00415],[@B32-cancers-11-00415],[@B33-cancers-11-00415],[@B34-cancers-11-00415],[@B35-cancers-11-00415],[@B36-cancers-11-00415],[@B38-cancers-11-00415],[@B39-cancers-11-00415],[@B40-cancers-11-00415],[@B44-cancers-11-00415],[@B45-cancers-11-00415],[@B46-cancers-11-00415],[@B47-cancers-11-00415],[@B49-cancers-11-00415],[@B51-cancers-11-00415],[@B52-cancers-11-00415],[@B53-cancers-11-00415],[@B54-cancers-11-00415]\] and one in exosome \[[@B8-cancers-11-00415]\]. Overall, 46 studies evaluated 69 miRNA markers and 19 miRNA panels (in total 88 miRNAs). All 46 studies quantified miRNA levels using quantitative real-time polymerase chain reaction (qRT-PCR), the most commonly used method for miRNA detection over the past 5 years. Only one study conducted by Fan et al. \[[@B33-cancers-11-00415]\] also used fluorescence quantum dots liquid bead array to quantify miRNA levels.

3.3. Diagnostic Performance of miRNA Markers {#sec3dot3-cancers-11-00415}
--------------------------------------------

Of the 88 circulating miRNAs included in the 46 studies, 22 miRNAs were reported in ≥ 2 studies ([Table 3](#cancers-11-00415-t003){ref-type="table"}). Most identified miRNAs were also included in panels, and only 31 miRNAs were not part of any panel ([Table S1](#app1-cancers-11-00415){ref-type="app"}). The smallest panel included only two miRNAs \[[@B10-cancers-11-00415],[@B34-cancers-11-00415],[@B50-cancers-11-00415]\], and the largest panel included 20 miRNAs \[[@B29-cancers-11-00415]\]. An overview of the diagnostic performance of all reported miRNAs and miRNA panels is shown in [Figure 2](#cancers-11-00415-f002){ref-type="fig"}A. For individual miRNAs, the median (range) sensitivity and specificity were 76.9% (33.9--99.2%) and 80% (28.2--100%) respectively. The median (range) sensitivity and specificity of miRNA panels were 76.3% (55.9--96%) and 79.6% (65.6--100%) respectively. A more detailed representation of miRNAs and miRNA panels with ≥80% sensitivity and ≥80% specificity is given in [Figure 2](#cancers-11-00415-f002){ref-type="fig"}B (17 individual miRNAs and 11 miRNA panels). Even though several individual miRNAs, such as miR-16-5p \[[@B33-cancers-11-00415]\] and miR-223 \[[@B48-cancers-11-00415]\] showed comparable performance as some of the panels, such as a 3-miRNA panel in Wang's study \[[@B39-cancers-11-00415]\], miRNA panels generally outperformed individual miRNAs for non-small cell lung cancer (NSCLC), with three miRNA panels showing ≥90% sensitivity and ≥90% specificity ([Figure 2](#cancers-11-00415-f002){ref-type="fig"}B). Two of the three panels were also externally validated \[[@B33-cancers-11-00415],[@B54-cancers-11-00415]\]. Two of 46 studies included LC cases of any histological subtypes \[[@B37-cancers-11-00415],[@B52-cancers-11-00415]\], 34 studies included NSCLC cases \[[@B8-cancers-11-00415],[@B9-cancers-11-00415],[@B14-cancers-11-00415],[@B15-cancers-11-00415],[@B17-cancers-11-00415],[@B18-cancers-11-00415],[@B21-cancers-11-00415],[@B24-cancers-11-00415],[@B25-cancers-11-00415],[@B28-cancers-11-00415],[@B30-cancers-11-00415],[@B31-cancers-11-00415],[@B32-cancers-11-00415],[@B33-cancers-11-00415],[@B34-cancers-11-00415],[@B35-cancers-11-00415],[@B36-cancers-11-00415],[@B38-cancers-11-00415],[@B39-cancers-11-00415],[@B40-cancers-11-00415],[@B41-cancers-11-00415],[@B42-cancers-11-00415],[@B43-cancers-11-00415],[@B44-cancers-11-00415],[@B45-cancers-11-00415],[@B46-cancers-11-00415],[@B47-cancers-11-00415],[@B48-cancers-11-00415],[@B50-cancers-11-00415],[@B51-cancers-11-00415],[@B53-cancers-11-00415],[@B54-cancers-11-00415],[@B55-cancers-11-00415],[@B56-cancers-11-00415]\], six studies included only ADC cases \[[@B19-cancers-11-00415],[@B23-cancers-11-00415],[@B26-cancers-11-00415],[@B27-cancers-11-00415],[@B29-cancers-11-00415],[@B49-cancers-11-00415]\], three studies included only SCC cases \[[@B10-cancers-11-00415],[@B16-cancers-11-00415],[@B20-cancers-11-00415]\], and one study included small cell lung cancer (SCLC) cases \[[@B57-cancers-11-00415]\]. Regarding subgroup analyses, five studies performed histology-specific analyses ([Table 1](#cancers-11-00415-t001){ref-type="table"} and [Table 2](#cancers-11-00415-t002){ref-type="table"}) \[[@B17-cancers-11-00415],[@B28-cancers-11-00415],[@B34-cancers-11-00415],[@B48-cancers-11-00415],[@B50-cancers-11-00415]\], and eight studies performed analyses according to cancer stage ([Table S2](#app1-cancers-11-00415){ref-type="app"}) \[[@B26-cancers-11-00415],[@B28-cancers-11-00415],[@B30-cancers-11-00415],[@B39-cancers-11-00415],[@B45-cancers-11-00415],[@B48-cancers-11-00415],[@B50-cancers-11-00415],[@B53-cancers-11-00415]\]. In histology-specific analyses, several studies reported differential sensitivity, specificity or AUC values in different histological subtypes (ADC and SCC) for the same miRNA or miRNA panel \[[@B17-cancers-11-00415],[@B28-cancers-11-00415],[@B34-cancers-11-00415],[@B48-cancers-11-00415],[@B50-cancers-11-00415]\]. This indicates that miRNAs could be differentially expressed in different histological subtypes of LC, but no histology-specific miRNA could be identified ([Table 1](#cancers-11-00415-t001){ref-type="table"} and [Table 2](#cancers-11-00415-t002){ref-type="table"}). In analyses according to cancer stage, several studies showed that diagnostic efficacy of either miRNAs or miRNA panels in advanced stage of LC seems to be better compared to early stage of LC, however, the differences with respect to AUCs were rather limited ([Table S2](#app1-cancers-11-00415){ref-type="app"}).

Of the 22 miRNAs reported at least twice, miR-21 was most frequently reported (13 studies), followed by miR-145, miR-20a, miR-24, miR-223, miR-155, miR-25, miR-152, miR-125a-5p, miR-126, miR-221 and miR-93 (all three to five studies) ([Table 3](#cancers-11-00415-t003){ref-type="table"}). Of note, higher frequency of reporting of the investigated markers does not go along with higher values of diagnostic performance parameters. For example, the median sensitivity and specificity of miR-21 were 69% (46.3--91%) and 71.9% (60--92%) respectively.

3.4. Direction of Dysregulation of Circulating miRNAs {#sec3dot4-cancers-11-00415}
-----------------------------------------------------

Of the 46 studies, 45 studies described the direction of dysregulation of miRNAs in blood, and only one study did not report information on miRNA dysregulation ([Table S1](#app1-cancers-11-00415){ref-type="app"}). Among the 22 miRNAs reported in ≥2 studies, inconsistent directions were reported for six miRNAs ([Table S3](#app1-cancers-11-00415){ref-type="app"}), whereas consistent direction of dysregulation was observed for most of the markers. For example, up-regulation of miR-24, miR-223, miR-155 and miR-221, and down-regulation of miR-126 were consistently reported in all studies reporting on these miRNAs regardless of histological subtype, stage or sample type ([Table S1](#app1-cancers-11-00415){ref-type="app"}). In addition, miR-21, the most frequently reported miRNA, was also up-regulated in both plasma and serum samples in all included studies, except one study reporting down-regulation of miR-21 in exosome \[[@B8-cancers-11-00415]\].

3.5. Comparison of miRNAs Profiles for LC Detection between Eastern Asian and Western Populations {#sec3dot5-cancers-11-00415}
-------------------------------------------------------------------------------------------------

We previously performed a systematic review of literature on circulating miRNAs for lung cancer detection in Western populations \[[@B12-cancers-11-00415]\]. A further update of this review until September 17th, 2018 identified a total number of 110 miRNAs, 34 of which were reported in ≥2 studies. We plotted Venn diagrams to illustrate the overlap of identified miRNAs between East Asian and Western populations. Forty-four miRNAs were reported in both populations ([Figure 3](#cancers-11-00415-f003){ref-type="fig"}A), which accounted for 50% of miRNAs reported in the East Asian populations, and 40% of miRNAs reported in the Western populations. Restricting miRNAs reported ≥2 times in each type of population, there were 12 overlapping miRNAs ([Figure 3](#cancers-11-00415-f003){ref-type="fig"}B), which account for 55% of miRNAs reported in East Asian and 35% of miRNAs reported in Western populations. Sixteen miRNAs were evaluated individually in both East Asian and Western populations, AUC values of which are shown in [Figure 4](#cancers-11-00415-f004){ref-type="fig"}. For some miRNAs showing differences in diagnostic performance were observed between East Asian and Western studies, but such differences were also seen within each type of study populations. Detailed information of the 16 miRNAs is provided in [Table S4](#app1-cancers-11-00415){ref-type="app"}.

4. Discussion {#sec4-cancers-11-00415}
=============

Our systematic literature review identified 46 studies that evaluated a total of 88 miRNA markers for LC diagnosis in East Asian populations. Sixteen of the 46 studies have incorporated individual miRNA markers as panels (with 2--20 markers). Three promising miRNA panels with ≥90% sensitivity and ≥90% specificity were discovered, two of which were verified externally \[[@B33-cancers-11-00415],[@B54-cancers-11-00415]\]. Diagnostic performance of circulating miRNA in East Asian populations was comparable to diagnostic performance in Western populations. Forty-four miRNAs were reported in both populations. No major differences in diagnostic performance by ethnicity of the same miRNA was observed.

In general, the performance of the investigated miRNAs and miRNA panels for detecting LC in East Asian populations appears promising, and in most cases the sum of the sensitivity and specificity by far exceeded 100% ([Figure 2](#cancers-11-00415-f002){ref-type="fig"}A). There were 17 individual miRNAs and 11 miRNA panels for which both sensitivity and specificity above 80% were reported ([Figure 2](#cancers-11-00415-f002){ref-type="fig"}B). Several miRNA panels even showed rather good diagnostic efficiency. For instance, Fan et al. \[[@B33-cancers-11-00415]\] used a panel composed of miR-20a-5p, miR-16-5p and miR-15b-5p in serum to discriminate NSCLC cases from healthy controls, and the sensitivity and specificity reached 94% and 94%, respectively, in the validation set. Chen et al. \[[@B54-cancers-11-00415]\] used a 10-miRNA panel in serum, and reported 93% sensitivity and 90% specificity in the validation set. Several miRNA panels were reported to be useful for the detection of early stage LC, with verified AUC values over 0.85 \[[@B8-cancers-11-00415],[@B10-cancers-11-00415],[@B48-cancers-11-00415]\]. However, most studies evaluated miRNAs or miRNA panels in samples of stage I--IV LC cases, the diagnostic efficiency of the reported markers or panels for early stage LC needs to be validated in true screening settings. Differences in the subgroup analyses for histology and stage of LC were rather small and relevant data were not sufficient to obtain robust results.

Aberrant expression of specific circulating miRNAs may provide important information for distinguishing LC histological subtypes or stages. However, subgroup analyses with respect to LC histological subtypes or stages have only been performed in a small proportion of the included studies \[[@B17-cancers-11-00415],[@B26-cancers-11-00415],[@B28-cancers-11-00415],[@B30-cancers-11-00415],[@B34-cancers-11-00415],[@B39-cancers-11-00415],[@B45-cancers-11-00415],[@B48-cancers-11-00415],[@B50-cancers-11-00415],[@B53-cancers-11-00415]\]. Even though histology-specific analysis identified variations of diagnostic indicators of miRNA in different subtypes, no histology-specific miRNA was discovered due to the overlap in profiles. Consistent findings were also observed in studies conducted in the Western populations. Stage-specific analyses in both the Eastern Asian and Western populations showed that diagnostic efficacy was better in advanced stage compared to early stage; however, the differences with respect to AUC were quite small.

Over the past decade, studies focusing on miRNA and LC have been emerging rapidly and have identified a number of LC-specific miRNA expression profiles. However, these miRNA expression profiles are not consistent among different studies \[[@B58-cancers-11-00415],[@B59-cancers-11-00415],[@B60-cancers-11-00415],[@B61-cancers-11-00415]\]. In this systematic review, the degree of overlap of LC-specific miRNAs reported by various studies was found to be low and inconsistent directions of dysregulation of miRNAs was observed. Similar findings were also noted among the Western studies \[[@B12-cancers-11-00415]\]. To be used as biomarkers for LC screening, miRNAs should show consistent degrees and direction of dysregulation in different settings \[[@B62-cancers-11-00415],[@B63-cancers-11-00415]\]. Possible sources of inconsistency of results across studies could include the use of different biospecimen or different analytical platforms. Ideally, future studies should involve different types of biospecimen and different types of analytical platforms in the same study population in order to further elucidate the role of these factors in miRNA profiling.

Further causes of the heterogeneity of reported miRNA biomarkers may be the differences in the characteristics of study populations. For the included studies in both East Asian and Western populations, we extracted demographic information such as age, sex and country, as these factors may affect the identification of miRNA markers \[[@B11-cancers-11-00415],[@B64-cancers-11-00415],[@B65-cancers-11-00415]\]. Cigarette smoking could also induce the dysregulation of some circulating miRNAs, which might be associated with smoking-related LC \[[@B47-cancers-11-00415],[@B66-cancers-11-00415],[@B67-cancers-11-00415]\]. However, information on smoking status was incomprehensive in most studied populations, especially in controls. Sample sizes of the majority of both East Asian and Western studies were rather small, which might have resulted in substantial random variation of LC-specific miRNAs identified among studies. In addition, miRNA profiles may change in different phases of cancer \[[@B68-cancers-11-00415]\]. Most studies in both East Asian and Western populations however recruited LC cases with various stage proportions.

The use of different miRNA detection protocols could also affect the identification of LC-specific miRNAs. Pre-analytical factors such as speed and duration of centrifugation may affect the amount of cell debris remaining in the sample supernatant (especially in plasma samples) and cause miRNA contaminations \[[@B69-cancers-11-00415],[@B70-cancers-11-00415],[@B71-cancers-11-00415],[@B72-cancers-11-00415]\]. Only a fraction of included studies in both East Asian and Western populations have applied a second high-speed centrifugation step to reduce the remaining cell debris ([Table S5](#app1-cancers-11-00415){ref-type="app"}). Moreover, reports on most studies did not specifically address potential hemolysis, which could result in an increase of multiple miRNA levels \[[@B70-cancers-11-00415],[@B71-cancers-11-00415],[@B73-cancers-11-00415],[@B74-cancers-11-00415]\]. Analytical factors such as differences in miRNA extraction and quantification methods could also contribute to the variability of identified LC-specific miRNAs \[[@B75-cancers-11-00415]\]. The extraction methods in the included studies were diverse ([Table S5](#app1-cancers-11-00415){ref-type="app"}), only few studies in both East Asian and Western populations have used miRNeasy kit which has been suggested to have better extraction efficiency compared to other kits \[[@B76-cancers-11-00415],[@B77-cancers-11-00415]\]. In addition, a very important yet unresolved issue is the normalization of miRNA expression data. Circulating miR-16 is usually used as endogenous control for normalization ([Table S5](#app1-cancers-11-00415){ref-type="app"}), however, it shows an unstable expression in the circulation of cancer patients as well as in hemolytic samples \[[@B71-cancers-11-00415],[@B78-cancers-11-00415],[@B79-cancers-11-00415]\]. Several new bioinformatics tools such as miRNA ratios and differentially expressed miRNA pairs have been developed to build up miRNA panels to reduce the analytical bias \[[@B80-cancers-11-00415],[@B81-cancers-11-00415],[@B82-cancers-11-00415]\]. These attempts so far have shown promising results but still require further validation.

The herein described circulating miRNAs have several advantages over some other markers of cancer detection: (i) miRNAs are extremely stable in cell-free fluids and in less than ideal sample handling conditions \[[@B79-cancers-11-00415],[@B83-cancers-11-00415],[@B84-cancers-11-00415]\], (ii) they can be measured repeatedly over time in a non-invasive manner \[[@B85-cancers-11-00415]\], (iii) they can be used to predict cancer in high-risk populations years in advance \[[@B80-cancers-11-00415],[@B82-cancers-11-00415],[@B86-cancers-11-00415]\] and (iv) the cost of analysis is relative low. Still, other blood-based markers have been proposed for LC detection, such as cytokeratin 19 fragment 21-1 (CYFRA21-1), carcinoembryonic antigen (CEA), tissue polypeptide specific antigen (TPS) or neuron-specific enolase (NSE). However, these markers are primarily utilized for monitoring of disease progression and tend to show suboptimal diagnostic value for LC with sensitivity values usually under 50% \[[@B81-cancers-11-00415],[@B87-cancers-11-00415]\]. Sanfiorenzo et al. \[[@B88-cancers-11-00415]\] developed a signature of 11 plasma miRNAs to discriminate healthy individuals from NSCLC patients which yielded 85% sensitivity and 82.9% specificity. This estimate of sensitivity was compared favorably with an estimated sensitivity of blood-based biomarkers, such as CYFRA 21-1, TPS and CEA, which ranged from 34% to 53% in the same study population. Recently, DNA methylation markers have showed good diagnostic efficacy for LC. Zhang et al. \[[@B89-cancers-11-00415]\] used a combination of F2RL3 methylation in whole blood and smoking exposure to predict LC incidence with an AUC value of 0.86 for participants ≥65 years. Since miRNA markers and DNA methylation markers both shown good diagnostic performance for LC, the combination of the two may offer an improvement of diagnostic efficiency in LC.

5. Conclusions {#sec5-cancers-11-00415}
==============

Our systematic review suggests a number of circulating miRNAs to be promising candidates for noninvasive LC detection in East Asian populations. The heterogeneity of reported LC-specific miRNA profiles in published studies needs to be addressed and protocols for the standardization of miRNA analysis procedures need to be put into place. Larger prospective studies, the improvement of miRNA detection technologies, the minimization of pre-analytical or analytical variability as well as the development of new analysis methods will be crucial to further reduce the bias in measurement and analysis and improve the diagnostic performance. Most importantly, however, will be the rigorous independent validation of identified promising miRNA algorithms or their combination with other biomarkers in prospective screening cohorts.

The following are available online at <https://www.mdpi.com/2072-6694/11/3/415/s1>, Figure S1: Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies, Figure S2: Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study, Table S1: Summary of studies reporting significant associations of miRNAs with lung cancer in East Asian populations, Table S2: Diagnostic performance of miRNAs and miRNA panels according to lung cancer stage in East Asian populations, Table S3: MiRNAs for which opposite directions of dysregulation were reported in lung cancer blood samples, Table S4: East Asian studies versus Western studies of miRNAs for lung cancer detection, Table S5: Protocols of blood miRNA detection.
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![Graphical representation of sensitivity versus specificity of analyzed miRNAs. Sensitivity is plotted on the y-axis while on the x-axis the false positive rate is presented (100-Specificity). (**A**) Overview of all analyzed miRNAs and miRNA panels and (**B**) more detailed representation of miRNAs and miRNA panels with ≥80% sensitivity and ≥80% specificity. Panel D: -145, -20a, -21, -223; Panel E: -146a, -222, -223; Panel F: let-7b-5p, let-7e-5p, -24-5p, -21-5p; Panel G: -628-3p, -339-3p, -425-3p, -532; Panel H: -628-3p, -425-3p, -532; Panel I (20 miRs): -451, -1290. -636, -30c, -22-3p, -19b, -486-5p, -20b, -93, -34b, -185, -126-5p, -93-3p, -1274a, -142-5p, -628-5p, -486-3p, -425, -645, -24; Panel J: -20a-5p, -16-5p, -15b-5p; Panel K: -148a, -148b, -152, -21; Panel L: -25, -125a-5p, -126; Panel O (10 miRs): -20a, -24, -25, -145, -152, -199a-5p, -221, -222, -223, -320. Abbreviations: LC: lung cancer; NSCLC: non-small cell lung cancer; ADC: adenocarcinoma; SCC: squamous cell carcinoma; SCLC: small cell lung cancer.](cancers-11-00415-g002){#cancers-11-00415-f002}

![Venn diagrams showing numbers of miRNAs with reported significant associations with lung cancer for Western and East Asian studies. (**A**) miRNAs reported in ≥1 study and (**B**) miRNAs reported in ≥2 studies.](cancers-11-00415-g003){#cancers-11-00415-f003}

![Graphical representation of Western studies versus East Asian studies of the diagnostic performance of miRNAs in lung cancer. Abbreviations: AUC: area under the curve; LC: lung cancer; NSCLC: non-small cell lung cancer; ADC: adenocarcinoma; SCC: squamous cell carcinoma.](cancers-11-00415-g004){#cancers-11-00415-f004}

cancers-11-00415-t001_Table 1

###### 

Diagnostic performance of miRNA markers in lung cancer in East Asian populations.

  Study ^a^                                     Cases vs. Controls   Specimen   Histology   Stage          miRNA     SEN       SPE            AUC          *p*-Value              
  --------------------------------------------- -------------------- ---------- ----------- -------------- --------- --------- -------------- ------------ ----------- ---------- --------------
  Zhao, 2018 \[[@B14-cancers-11-00415]\] ^b^    108/54               /          61/NA       serum          NSCLC     I--IV     miR-141        /            /           0.86       \<0.001 ^c^
  Sun, 2018 \[[@B15-cancers-11-00415]\] ^b^     196/77               /          58/NA       serum          NSCLC     I--IV     miR-770        68           89          0.84       \<0.01 ^c^
  Shan, 2018 \[[@B16-cancers-11-00415]\] ^b^    102/101              /          100/100     plasma         SCC       I--III    miR-181a-5p    /            /           0.73       \<0.001 ^c^
  miR-21-5p                                     /                    /          0.74        \<0.001 ^c^                                                                           
  miR-106a-5p                                   /                    /          0.74        \<0.001 ^c^                                                                           
  miR-93-5p                                     /                    /          0.69        \<0.001 ^c^                                                                           
  Qin, 2018 \[[@B17-cancers-11-00415]\]         146/40               63/NA      73/NA       serum          NSCLC     I--IV     miR-342-3p     60           94          0.89       \<0.01 ^c^
  78/40                                         /                    /          SCC         miR-342-3p     83        76        0.87           \<0.01 ^c^                          
  68/40                                         /                    /          ADC         miR-342-3p     83        82        0.90           \<0.01 ^c^                          
  Bao, 2018 \[[@B18-cancers-11-00415]\] ^b^     80/75                /          61/60       serum          NSCLC     I--IV     miR-10a-5p     66           73          0.71       \<0.0001 ^c^
  miR-196a-5p                                   68                   78         0.79        0.0018 ^c^                                                                            
  Zhang, 2017 \[[@B20-cancers-11-00415]\] ^b^   102/108              /          100/100     Serum          SCC       I--III    miR-106a-5p    /            /           0.83       \<0.001 ^c^
  miR-20a-5p                                    /                    /          0.80        \<0.001 ^c^                                                                           
  miR-93-5p                                     /                    /          0.82        \<0.001 ^c^                                                                           
  Wang, 2017 \[[@B24-cancers-11-00415]\]        127/60               58/59      62/58       serum          NSCLC     I--IV     miR-98         80           82          0.86       \<0.01 ^c^
  Zhou, 2017 \[[@B19-cancers-11-00415]\] ^b^    108/94               /          43/46       plasma         ADC       I--IV     miR-19b-3p     /            /           0.62       \<0.001 ^c^
  miR-21-5p                                     /                    /          0.69        \<0.001 ^c^                                                                           
  miR-221-3p                                    /                    /          0.68        \<0.001 ^c^                                                                           
  miR-409-3p                                    /                    /          0.61        \<0.001 ^c^                                                                           
  miR-425-5p                                    /                    /          0.66        \<0.001 ^c^                                                                           
  miR-584-5p                                    /                    /          0.69        \<0.001 ^c^                                                                           
  Zhang, 2017 \[[@B21-cancers-11-00415]\]       129/83               60/60      63/58       plasma         NSCLC     I--II     miR-145        81           89          0.89       \<0.0001 ^c^
  miR-20a                                       80                   88         0.89        \<0.0001 ^c^                                                                          
  miR-21                                        78                   86         0.84        \<0.001 ^c^                                                                           
  miR-223                                       70                   84         0.81        \<0.001 ^c^                                                                           
  Yu, 2017 \[[@B22-cancers-11-00415]\] ^b^      50/30                /          82/83       plasma         SCLC      I--IV     miR-92a-2-5p   56           100         0.76       \<0.001 ^c^
  Yang, 2017 \[[@B23-cancers-11-00415]\] ^b^    113/30               /          52/NA       serum          ADC       I--IV     miR-31         /            /           0.84       \<0.01 ^c^
  Shang, 2017 \[[@B25-cancers-11-00415]\]       127/112              55/44      65/56       serum          NSCLC     I--IV     miR-22         99           84          0.92       \<0.001
  miR-126                                       83                   96         0.87        \<0.001                                                                               
  Lv, 2017 \[[@B26-cancers-11-00415]\]          120/120              60/59      52/51       serum          ADC       I--IV     miR-103        /            /           0.80       \<0.0001 ^c^
  miR-146a                                      /                    /          0.90        \<0.0001 ^c^                                                                          
  miR-151                                       /                    /          0.85        \<0.0001 ^c^                                                                          
  miR-221                                       /                    /          0.79        \<0.0001 ^c^                                                                          
  miR-222                                       /                    /          0.86        \<0.0001 ^c^                                                                          
  miR-223                                       /                    /          0.91        \<0.0001 ^c^                                                                          
  Zhu, 2016 \[[@B9-cancers-11-00415]\]          112/40               59/58      54/55       serum          NSCLC     0--IIIB   miR-182        63           80          0.73       \<0.0001
  miR-183                                       41                   83         0.63        0.0091                                                                                
  miR-210                                       34                   100        0.62        0.0121                                                                                
  miR-126                                       61                   93         0.79        \<0.0001                                                                              
  Wang, 2016 \[[@B27-cancers-11-00415]\]        82/91                /          /           plasma         ADC       I--II     miR-628-3p     43           91          0.73       \<0.001 ^c^
  miR-339-3p                                    65                   71         0.72        \<0.001 ^c^                                                                           
  miR-425-3p                                    67                   68         0.73        \<0.001 ^c^                                                                           
  miR-532                                       54                   80         0.66        \<0.001 ^c^                                                                           
  Wang, 2016 \[[@B28-cancers-11-00415]\]        54/15                60/51      /           serum          NSCLC     I--IV     miR-1244       82           80          0.83       /
  26/15                                         NA/51                /          ADC         miR-1244       77        80        0.79           \<0.05 ^c^                          
  18/15                                         NA/51                /          SCC         miR-1244       83        80        0.85           \<0.05 ^c^                          
  Sun, 2016 \[[@B30-cancers-11-00415]\]         50/60                67/62      76/78       serum          NSCLC     I--IV     miR-21         /            /           0.87       0.000
  Su, 2016 \[[@B32-cancers-11-00415]\] ^b^      100/100              /          65/70       plasma         NSCLC     I--III    miR-195        78           86          0.89       \<0.01 ^c^
  Peng, 2016 \[[@B32-cancers-11-00415]\]        120/71               60/58      72/62       serum          NSCLC     I--IV     miR-1254       **97**       **39**      **0.68**   0.000
  miR-485-5p                                    **95**               **63**     **0.79**    0.000                                                                                 
  miR-574-5p                                    **99**               **28**     **0.64**    0.002                                                                                 
  Gao, 2016 \[[@B10-cancers-11-00415]\]         90/90                62/62      80/78       plasma         SCC       I         miR-324-3p     **72**       **76**      **0.79**   /
  miR-1285                                      **87**               **78**     **0.85**    /                                                                                     
  Fan, 2016 \[[@B33-cancers-11-00415]\] ^d^     94/58                60/58      54/53       serum          NSCLC     I--IIIB   miR-15b-5p     52           74          /          0.006 ^c^
  miR-16-5p                                     88                   86         /           0.0001 ^c^                                                                            
  miR-17-5p                                     82                   68         /           0.0001 ^c^                                                                            
  miR-19-3p                                     83                   67         /           0.0001 ^c^                                                                            
  miR-20a-5p                                    76                   90         /           0.0001 ^c^                                                                            
  miR-28-3p                                     71                   79         /           0.0001 ^c^                                                                            
  miR-92a-3p                                    87                   66         /           0.0001 ^c^                                                                            
  Zhou, 2015 \[[@B34-cancers-11-00415]\]        87/61                59/56      63/52       serum          NSCLC     I--IV     miR-194        /            /           0.66       /
  miR-652                                       /                    /          0.82        /                                                                                     
  miR-660                                       /                    /          0.71        /                                                                                     
  52/61                                         NA/56                NA/52      ADC         miR-194        /         /         0.63           0.0192 ^c^                          
  miR-652                                       /                    /          0.82        \<0.0001 ^c^                                                                          
  miR-660                                       /                    /          0.72        \<0.0001 ^c^                                                                          
  35/61                                         NA/56                NA/52      SCC         miR-194        /         /         0.70           0.0007 ^c^                          
  miR-652                                       /                    /          0.81        \<0.0001 ^c^                                                                          
  miR-660                                       /                    /          0.70        0.0003 ^c^                                                                            
  Zhao, 2015 \[[@B35-cancers-11-00415]\]        80/60                58/55      61/52       serum          NSCLC     /         miR-21         74           72          0.81       0.001 ^c^
  Yang, 2015 \[[@B36-cancers-11-00415]\] ^b^    152/300              /          65/69       serum          NSCLC     I--IV     miR-148a       85           83          0.90       \<0.001 ^c^
  miR-148b                                      83                   83         0.90        \<0.001 ^c^                                                                           
  miR-152                                       75                   77         0.82        \<0.001 ^c^                                                                           
  miR-21                                        69                   71         0.81        \<0.001 ^c^                                                                           
  Yan, 2015 \[[@B37-cancers-11-00415]\] ^b^     300/300              /          /           plasma         Any LC    I--IV     miR-31         77           75          0.79       \<0.001 ^c^
  Wang, 2015 \[[@B38-cancers-11-00415]\]        70/70                64/64      61/61       serum          NSCLC     /         miR-125a-5p    74           56          0.71       \<0.0001 ^c^
  miR-145                                       93                   61         0.84        \<0.0001 ^c^                                                                          
  miR-146a                                      84                   59         **0.78**    \<0.0001 ^c^                                                                          
  Wang, 2015 \[[@B39-cancers-11-00415]\]        94/111               NA/60      NA/52       serum          NSCLC     IA--IIB   miR-125a-5p    88           75          **0.83**   /
  miR-25                                        83                   75         **0.82**    /                                                                                     
  miR-126                                       83                   63         **0.79**    /                                                                                     
  Wang, 2015 \[[@B40-cancers-11-00415]\] ^e^    63/63                62/60      78/59       serum          NSCLC     I--IV     miR-483-5p     /            /           **0.66**   0.002
  miR-193a-3p                                   /                    /          **0.81**    \<0.0001                                                                              
  miR-214                                       /                    /          **0.78**    \<0.0001                                                                              
  miR-25                                        /                    /          **0.84**    \<0.0001                                                                              
  miR-7                                         /                    /          **0.81**    \<0.0001                                                                              
  Li, 2015 \[[@B41-cancers-11-00415]\]          11/11                59/55      64/55       plasma         NSCLC     I--IIIA   miR-486        91           82          0.93       0.0008 ^c^
  miR-150                                       82                   82         0.75        0.0488 ^c^                                                                            
  Guo, 2015 \[[@B42-cancers-11-00415]\] ^b^     126/50               /          64/NA       plasma         NSCLC     I--IV     miR-204        **76**       **82**      **0.81**   \<0.001 ^c^
  Dou, 2015 \[[@B43-cancers-11-00415]\]         120/360              63/NA      60/NA       plasma         NSCLC     I--IV     let-7c         72           78          0.71       0.006
  miR-152                                       86                   81         0.85        0.0002                                                                                
  Zhu, 2014 \[[@B44-cancers-11-00415]\]         36/44                /          /           serum          NSCLC     I         miR-125a-5p    54           75          0.65       0.021
  let-7e                                        50                   83         0.64        0.0317                                                                                
  Zhu, 2014 \[[@B45-cancers-11-00415]\]         70/48                59/NA      80/NA       serum          NSCLC     I--IV     miR-29c        66           74          0.68       0.0004
  miR-429                                       54                   81         0.71        \<0.0001                                                                              
  Li, 2014 \[[@B46-cancers-11-00415]\] ^b^      514/54               /          53/NA       serum          NSCLC     I--IV     miR-499        74           93          0.91       \<0.001 ^c^
  Huang, 2014 \[[@B47-cancers-11-00415]\]       53/65                57/55      /           serum          NSCLC     /         let-7i-3p      /            /           **0.89**   \<0.001 ^c^
  miR-154-5p                                    /                    /          **0.96**    \<0.001 ^c^                                                                           
  Geng, 2014 \[[@B48-cancers-11-00415]\] ^b^    126/60               /          69/60       plasma         NSCLC     I--II     miR-20a        **83**       **81**      **0.89**   \<0.001 ^c^
  miR-223                                       **87**               **86**     **0.94**    \<0.001 ^c^                                                                           
  miR-21                                        **67**               **68**     **0.77**    \<0.001 ^c^                                                                           
  miR-155                                       **86**               **84**     **0.92**    \<0.001 ^c^                                                                           
  miR-145                                       **70**               **68**     **0.77**    \<0.001 ^c^                                                                           
  45/60                                         /                    /          ADC         I--II          miR-20a   **87**    **83**         **0.90**     /                      
  miR-223                                       **80**               **82**     **0.91**    /                                                                                     
  miR-21                                        **60**               **60**     **0.63**    /                                                                                     
  miR-155                                       **87**               **87**     **0.93**    /                                                                                     
  miR-145                                       **71**               **70**     **0.77**    /                                                                                     
  64/60                                         /                    /          SCC         I--II          miR-20a   **97**    **97**         **0.98**     /                      
  miR-223                                       **95**               **93**     **0.98**    /                                                                                     
  miR-21                                        **91**               **90**     **0.97**    /                                                                                     
  miR-155                                       **92**               **90**     **0.96**    /                                                                                     
  miR-145                                       **95**               **95**     **0.97**    /                                                                                     
  Gao, 2014 \[[@B49-cancers-11-00415]\]         36/32                55/53      31/31       serum          ADC       I--IV     miR-155        72           69          0.76       0.000
  Tang, 2013 \[[@B50-cancers-11-00415]\]        34/32                65/66      65/81       plasma         NSCLC     I--III    miR-21         **53**       **72**      **0.71**   /
  miR-145                                       **56**               **56**     **0.66**    /                                                                                     
  miR-155                                       **68**               **66**     **0.74**    /                                                                                     
  Li, 2013 \[[@B51-cancers-11-00415]\]          60/30                54/57      70/50       serum          NSCLC     I--IV     miR-210        79           74          0.78       \<0.005 ^c^
  Wang, 2012 \[[@B52-cancers-11-00415]\]        31/39                61/46      71/23       serum          Any LC    I--IV     miR-21         87           74          0.88       \<0.001 ^c^
  Le, 2012 \[[@B53-cancers-11-00415]\]          82/50                59/NA      56/NA       serum          NSCLC     I--IV     miR-21         46           92          0.69       0.0058 ^c^
  miR-205                                       85                   72         0.78        0.0298 ^c^                                                                            
  miR-30d                                       76                   80         0.74        0.0147 ^c^                                                                            
  miR-24                                        76                   64         0.83        \<0.0001 ^c^                                                                          
  Wei, 2011 \[[@B55-cancers-11-00415]\]         77/36                60/56      71/75       plasma         NSCLC     I--IV     miR-21         61           83          0.73       \<0.0001
  Wei, 2011 \[[@B56-cancers-11-00415]\]         63/30                61/57      71/67       plasma         NSCLC     I--IV     miR-21         76           70          0.78       \<0.0001

^a^ all studies listed in the table were from China; ^b^ no mean age or median age but age distribution reported; ^c^ *p*-value represents the difference of miRNA levels between cases and controls (all other *p*-values represent the statistical significance of AUC values); ^d^ miRNAs detected with fluorescence quantum dots liquid bead array (all other studies detected with qRT-PCR); ^e^ USA validation set not included; SENs, SPEs and AUCs in bold fonts represent results from validation set (non-bold fonts represent results without validation). Abbreviations: SEN: sensitivity; SPE: specificity; AUC: area under the curve; LC: lung cancer; NSCLC: non-small cell lung cancer; ADC: adenocarcinoma; SCC: squamous cell carcinoma; NA: not available.

cancers-11-00415-t002_Table 2

###### 

Diagnostic performance of miRNA panels in lung cancer in East Asian populations.

  Study ^a^                                     Cases vs. Controls   Specimen   Histology   Stage        miRNA    SEN        SPE              AUC                
  --------------------------------------------- -------------------- ---------- ----------- ------------ -------- ---------- ---------------- -------- --------- ----------
  Shan, 2018 \[[@B16-cancers-11-00415]\] ^b^    15/15                /          100/100     plasma       SCC      I--III     Panel A          /        /         **0.91**
  Zhang, 2017 \[[@B20-cancers-11-00415]\] ^b^   34/36                /          100/100     serum        SCC      I--III     Panel B          /        /         **0.95**
  Zhou, 2017 \[[@B19-cancers-11-00415]\] ^b^    33/30                /          45/47       plasma       ADC      I--IV      Panel C          **73**   **80**    **0.84**
  Zhang, 2017 \[[@B21-cancers-11-00415]\]       129/83               60/60      63/58       plasma       NSCLC    I--II      Panel D          82       90        0.90
  LV, 2017 \[[@B26-cancers-11-00415]\]          120/120              60/59      52/51       serum        ADC      I--IV      Panel E          **84**   **91**    **0.95**
  72/120                                        NA/59                NA/51      I           /            /        **0.94**                                       
  31/120                                        NA/59                NA/51      II          /            /        **0.97**                                       
  10/120                                        NA/59                NA/51      III         /            /        **0.95**                                       
  Jin, 2017 \[[@B8-cancers-11-00415]\]          47/13                /          /           exosome      NSCLC    I          Panel F          **80**   **92**    **0.90**
  Wang, 2016 \[[@B27-cancers-11-00415]\]        82/91                /          /           plasma       ADC      I--II      Panel G          90       99        0.98
  Panel H                                       92                   98         0.97                                                                             
  Tai, 2016 \[[@B29-cancers-11-00415]\]         110/52               65/66      56/58       serum        ADC      I--III     Panel I          **89**   **100**   **0.98**
  Gao, 2016 \[[@B10-cancers-11-00415]\]         90/90                62/62      80/78       plasma       SCC      I          -324-3p, -1285   **85**   **82**    **0.89**
  Fan, 2016 \[[@B33-cancers-11-00415]\] ^c^     70/54                60/58      60/54       serum        NSCLC    I--IIIB    Panel J          **94**   **94**    /
  Zhou, 2015 \[[@B34-cancers-11-00415]\]        87/61                59/56      63/52       serum        NSCLC    I--IV      -652, -660       /        /         **0.86**
  52/61                                         NA/56                NA/52      ADC         -652, -660   /        /          **0.85**                            
  35/61                                         NA/56                NA/52      SCC         -652, -660   /        /          **0.87**                            
  Yang, 2015 \[[@B36-cancers-11-00415]\] ^b^    152/300              /          65/69       serum        NSCLC    I--IV      Panel K          96       91        0.98
  Wang, 2015 \[[@B39-cancers-11-00415]\]        142/111              61/60      61/52       serum        NSCLC    IA--IV     Panel L          **88**   **83**    **0.93**
  Wang, 2015 \[[@B40-cancers-11-00415]\] ^d^    63/63                62/60      78/59       serum        NSCLC    I--IV      Panel M          **89**   **68**    **0.82**
  Tang, 2013 \[[@B50-cancers-11-00415]\]        34/32                65/66      65/81       plasma       NSCLC    I--III     -21, -145        **74**   **81**    **0.85**
  -21, -145                                     **56**               **66**     **0.73**                                                                         
  -145, -155                                    **79**               **78**     **0.83**                                                                         
  Panel N                                       **77**               **81**     **0.87**                                                                         
  40/60                                         NA/66                NA/77                  ADC          I--III   Panel N    71               78       /         
  9/60                                          NA/66                NA/77                  SCC          I--III   Panel N    67               78       /         
  Chen, 2012 \[[@B54-cancers-11-00415]\]        200/110              60/59      79/72       serum        NSCLC    I--IV      Panel O          **93**   **90**    **0.97**

^a^ All studies listed in the table were from China, except Tai \[[@B29-cancers-11-00415]\] which was from Japan; ^b^ no mean age or median age but age distribution reported; ^c^ miRNAs detected with fluorescence quantum dots liquid bead array (all other studies detected with qRT-PCR); ^d^ USA validation set not included; SENs, SPEs and AUCs in bold fonts represent results from validation set (non-bold fonts represent results without validation). Panel A: -106a-5p, -20a-5p, -93-5p; Panel B: -181a-5p, -21-5p, -106a-5p, -93-5p; Panel C: -19b-3p, -21-5p, -221-3p, -409-3p, -425-5p, -584-5p; Panel D: -145, -20a, -21, -223; Panel E: -146a, -222, -223; Panel F: let-7b-5p, let-7e-5p, -24-5p, -21-5p; Panel G: -628-3p, -339-3p, -425-3p, -532; Panel H: -628-3p, -425-3p, -532; Panel I (20 miRs): -451, -1290. -636, -30c, -22-3p, -19b, -486-5p, -20b, -93, -34b, -185, -126-5p, -93-3p, -1274a, -142-5p, -628-5p, -486-3p, -425, -645, -24; Panel J: -20a-5p, -16-5p, -15b-5p; Panel K: -148a, -148b, -152, -21; Panel L: -25, -125a-5p, -126; Panel M: -214, -483-5p, -193a-3p, -25, -7; Panel N: -21, -145, -155; Panel O (10 miRs): -20a, -24, -25, -145, -152, -199a-5p, -221, -222, -223, -320. Abbreviations: SEN: sensitivity; SPE: specificity; AUC: area under the curve; LC: lung cancer; NSCLC: non-small cell lung cancer; ADC: adenocarcinoma; SCC: squamous cell carcinoma; NA: not available.

cancers-11-00415-t003_Table 3

###### 

Summary of studies reporting associations of miRNAs with lung cancer in East Asian populations (only miRNAs that have been reported in ≥2 studies are shown).

  Study                                     miR-21   miR-145   miR-20a   miR-24   miR-223   miR-155   miR-25   miR-152   miR-125a   miR-126   miR-221   miR-93   miR-210   miR-486   miR-425   miR-19b   miR-22   let-7e   miR-146a   miR-222   miR-31   miR-106a
  ----------------------------------------- -------- --------- --------- -------- --------- --------- -------- --------- ---------- --------- --------- -------- --------- --------- --------- --------- -------- -------- ---------- --------- -------- ----------
  Shan, 2018 \[[@B16-cancers-11-00415]\]    ○↑                                                                                                          ○↑                                                                                               ○↑
  Zhang, 2017 \[[@B20-cancers-11-00415]\]                      ○↑                                                                                       ○↑                                                                                               ○↑
  Zhou, 2017 \[[@B19-cancers-11-00415]\]    ○↑                                                                                                ○↑                                               ○↑                                                        
  Zhang, 2017 \[[@B21-cancers-11-00415]\]   ○↑       ○↑        ○↑                 ○↑                                                                                                                                                                     
  Yu, 2017 \[[@B22-cancers-11-00415]\]                                                                                                                                                                                                                   
  Yang, 2017 \[[@B23-cancers-11-00415]\]                                                                                                                                                                                                        △↑       
  Shang, 2017 \[[@B25-cancers-11-00415]\]                                                                                           △↓                                                                   △↑                                              
  Lv, 2017 \[[@B26-cancers-11-00415]\]                                            ○↑                                                          △↑                                                                           ○↑         ○↑                 
  Jin, 2017 \[[@B8-cancers-11-00415]\]      ○↓                           ○↑                                                                                                                                       ○↓                                     
  Zhu, 2016 \[[@B9-cancers-11-00415]\]                                                                                              △↓                           △↑                                                                                      
  Wang, 2016 \[[@B27-cancers-11-00415]\]                                                                                                                                             ○↑                                                                  
  Tai, 2016 \[[@B29-cancers-11-00415]\]                                  ○                                                                              ○                  ○         ○         ○         ○                                               
  Sun, 2016 \[[@B30-cancers-11-00415]\]     △↑                                                                                                                                                                                                           
  Fan, 2016 \[[@B33-cancers-11-00415]\]                        ○↓                                                                                                                                                                                        
  Zhao, 2015 \[[@B35-cancers-11-00415]\]    △↑                                                                                                                                                                                                           
  Yang, 2015 \[[@B36-cancers-11-00415]\]    ○↑                                                                 ○↓                                                                                                                                        
  Yan, 2015 \[[@B37-cancers-11-00415]\]                                                                                                                                                                                                         △↑       
  Wang, 2015 \[[@B38-cancers-11-00415]\]             △↑                                                                  △↑                                                                                                △↑                            
  Wang, 2015 \[[@B39-cancers-11-00415]\]                                                              ○↓                 ○↓         ○↓                                                                                                                   
  Wang, 2015 \[[@B40-cancers-11-00415]\]                                                              ○↑                                                                                                                                                 
  Li, 2015 \[[@B41-cancers-11-00415]\]                                                                                                                                     △↑                                                                            
  Dou, 2015 \[[@B43-cancers-11-00415]\]                                                                        △↓                                                                                                                                        
  Zhu, 2014 \[[@B44-cancers-11-00415]\]                                                                                  △↓                                                                                       △↓                                     
  Geng, 2014 \[[@B48-cancers-11-00415]\]    △↑       △↑        △↑                 △↑        △↑                                                                                                                                                           
  Gao, 2014 \[[@B49-cancers-11-00415]\]                                                     △↑                                                                                                                                                           
  Tang, 2013 \[[@B50-cancers-11-00415]\]    ○↑       ○↓                                     ○↑                                                                                                                                                           
  Li, 2013 \[[@B51-cancers-11-00415]\]                                                                                                                           △↑                                                                                      
  Wang, 2012 \[[@B52-cancers-11-00415]\]    △↑                                                                                                                                                                                                           
  Le, 2012 \[[@B53-cancers-11-00415]\]      △↑                           △↑                                                                                                                                                                              
  Chen, 2012 \[[@B54-cancers-11-00415]\]             ○↑        ○↑        ○↑       ○↑                  ○↑       ○↑                             ○↑                                                                                      ○↑                 
  Wei, 2011 \[[@B55-cancers-11-00415]\]     △↑                                                                                                                                                                                                           
  Wei, 2011 \[[@B56-cancers-11-00415]\]     △↑                                                                                                                                                                                                           
  Total                                     13       5         5         4        4         3         3        3         3          3         3         3        2         2         2         2         2        2        2          2         2        2

○ represents miRNAs which are part of a panel; △ represents miRNAs which have only been analyzed individually and not as a part of a miRNA panel; ↑ represents up-regulation; ↓ represents down-regulation; [Table S1](#app1-cancers-11-00415){ref-type="app"} provides all miRNAs for which significant associations with lung cancer have been reported.
